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Abstract
Background: Gastric epithelial hyper-proliferation was reported in patients with Helicobacter pylori (H. pylori)–
infected gastric mucosa with intestinal metaplasia (IM) changes. In patients with gastric ulcer (GU) and IM, the GU
may have a different healing rate in comparison to patients without IM. This study aimed to compare the
difference in GU healing between H. pylori–infected patients with IM and those without IM.
Methods: We retrospectively analyzed patients at the Keelung Chung Gung Memorial Hospital during the period
from March 2005 to January 2011. The inclusion criteria were: 1) endoscopic findings of GU and biopsy histological
examination plus rapid urease test indicating H. pylori infection; 2) gastric IM adjacent to a GU but with no atrophic
gastritis changes; 3) patients receiving H. pylori eradication triple therapy and 8 weeks of maintenance therapy with
a proton pump inhibitor; and 4) patients receiving follow-up endoscopy within the 3rd and the 4th months after
treatment.
Results: In total, 327 patients with GU and H. pylori infection (136 with IM and 191 without IM) were included.
Patients with IM had a higher GU healing rate than those without IM (91.9% vs. 84.3%, P = 0.040). Multivariate
logistical regression analysis revealed that failure of H. pylori eradication (Odds = 4.013, 95% CI: 1.840–8.951, P < 0.
001) and gastric IM (Odds = 0.369, 95% CI: 0.168–0.812, P = 0.013) were the predictors of non-healing GU following
treatment.
Conclusions: Patient with gastric IM change may have a higher GU healing rate than those without gastric IM.
However, successful H. pylori eradication is a more important factor for GU healing than gastric IM.
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Background
Intestinal metaplasia (IM) is a common finding in pa-
tients with Helicobacter pylori (H. pylori) infection. The
prevalence of IM in patients with H. pylori infection is
30–40% in patients approximately 50 years old [1, 2].
Some studies revealed that the Wingless-Int (Wnt)/β ca-
tenin pathway plays an important role in the progression
of H. pylori-related IM [3–6]. The Wnt signal transduc-
tion pathway is also important in intestinal epithelial
homeostasis, wound repair and epithelial proliferation
[7]. Gastric epithelial hyperproliferation has been
observed in patients with gastritis and IM caused by H.
pylori infection [8–11]. Epithelial cell proliferation is one
of the mechanisms governing the repair of a gastric ulcer
(GU) [12–14]. Patients with a condition of IM near the
GU might have a different outcome of GU healing due
to gastric mucosal hyperproliferation. To the best of our
knowledge, no study has analyzed whether IM influences
GU healing or H. pylori eradication. This study aimed to
compare the difference in GU healing between H. pyl-
ori–infected patients with and those without IM adjacent
to the GU.
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Methods
We retrospectively analyzed the clinical presentations,
endoscopic findings and pathologic records of all pa-
tients treated for peptic ulcers at Keelung Chang Gung
Memorial Hospital from March 2005 to January 2011.
The inclusion criteria in the study were: patients with
esophagogastroduodenoscopy (EGD) evidence of active
GU in the gastric antrum or body; patients with histo-
logical findings by GU biopsy and rapid urease tests in-
dicating H. pylori infection with or without IM change;
patients who received standard triple therapy (including
proton pump inhibitor (PPI), lansoprazole 30 mg or
esomerpazole 40 mg, 1 g amoxicillin, and 500 mg clari-
thromycin twice daily for 7 days) and 8 weeks of main-
tenance PPI therapy; and patients receiving follow-up
EGD and undergoing a rapid urease test and a histo-
logical study within the 3rd and the 4th month following
treatment. The exclusion criteria were patients receiving
PPI or antibiotics two weeks before any of the follow-up
EGD studies, and patients taking non-steroid anti-
inflammatory drugs (NSAIDs) or aspirin during the
healing phase.
If a patient had several EGD studies, only the findings
of the 1st and 2nd (follow-up) EGD studies were included
in the analysis. The exclusion criteria included patients
with underlying malignancy, gastric malignancy revealed
by GU biopsy or dysplasia change detected via GU bi-
opsy. In some patients, long-term H. pylori infection will
induce a progressive gastric atrophy including loss of
acid-producing parietal cells. Gastric atrophy leads to
lowered gastric acid output which might influence GU
healing [15]. Moreover, this study aimed to elucidate the
influence of IM adjacent to GU on GU healing and the
data of intra-gastric pH could not be available in this
retrospective study. Patients with gastric mucosal atro-
phy according to the results of GU biopsy were also ex-
cluded to avoid low gastric acid interfering with GU
healing in this study.
Endoscopic study
Patients who experienced epigastric pain, dyspepsia or
acid reflux symptoms received EGD. Wide base ulcer
was defined as GU base more than 1.5 cm in size. Dur-
ing the EGD study, GU biopsies (4 specimens from each
GU margin mucosa, another specimen from the gastric
antrum and one from the incisura angularis of corpus)
were obtained except in patients with active ulcer bleed-
ing or NSAID-related shallow ulcers. The rapid urease
test (RUT) was administered to confirm the presence of
H. pylori infection. Patients with positive results from
both the histological examination and RUT test were in-
cluded. In patients who had completed standard triple
therapy for H. pylori eradication and maintenance PPI
therapy, EGD was performed between the 3rd and the
4th month after treatment to evaluate the status of gas-
tric ulcer healing and H. pylori eradication success.
Therefore, biopsies were repeated for histological ana-
lysis and RUT, likewise to the initial EGD. Three stages
of GU were defined by endoscopy, based on the cycle of
ulcer formation and resolution. Gastric healed ulcer in
this study was defined as the regeneration of epithelium
that completely covered the floor of the ulcer (scarring
status), replacing the white coating ulcer base. Patients
with partially healing GU (not scarring status) or active
GU detected in the following EGD were recognized as
persistent GU in this study.
Histology and immunohistochemical (IHC) stain for H.
pylori detection
All patients received GU biopsy for histology (hematoxylin
and eosin) and IHC staining (polyclone, Zytomed Systems
GmbH, Berlin, Germany) to evaluate H. pylori infection
status. Histological sections of all biopsies were routinely
examined to determine H. pylori infection, IM, atrophic
gastritis and malignancy. Atrophy of the gastric mucosa
was defined as loss of glandular tissue and mucosal thin-
ning changes. IM was detected on the basis of the mor-
phological features in the stomach observed by
performing H & E and Alcian blue staining [16–18]. This
study applied the most widely used classification, in which
there are two types of IM:
1) Complete type IM: presence of small intestinal-type
mucosa with goblet cells, a brush border and eosino-
philic enterocytes.
2) Incomplete type IM: presence of colonic epithelium
with multiple, irregular mucin droplets of variable
size in the cytoplasm and absence of a brush border.
IM was scored according to the visual analog scale of
the updated Sydney classification [16]. The results of the
histological analyses were reviewed by a single experi-
enced pathologist (Dr. Chang LC).
Rapid urease test (RUT)
RUT (Pronto dry test; Medical Instruments Corporation,
Switzerland) was performed. The sensitivity and specifi-
city of RUT for detecting H. pylori infection were 99 and
96%, respectively [19].
Antigen Ki-67 stain for epithelial cell proliferation
For patients with adequate residual biopsy specimens
from GU margin after staining with an H. pylori anti-
body, an additional Ki-67 IHC stain was applied to as-
sess cell proliferation. Antigen Ki-67 IHC staining was
performed using DAKO autostain agent (Cytomation,
Carpinteria, CA). REAL EnVision Detection System,
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Peroxidase/diaminobenzidine (DAB) (K5007, DAKO)
was used to visualize the staining.
Digital data analysis
Digital data analysis was performed with computer
software to prevent manual or inter-observer bias for
the Ki-67 index score counting. The digital data analysis
was processed with ImageJ (1.45i) [20]. The color decon-
volution plug-in was used to separate the stains into two
8-bit component images: the DAB image and the
hematoxylin image. The DAB image was used for dens-
ity measurement. We calculated the percentage of posi-
tively stained nuclei (labeling index) by using a color
deconvolution algorithm to separate the staining
Fig. 1 Left side: Photomicrographs of gastric intestinal metaplasia. Gastric mucosa on the left show intestinal metaplasia with histological features
similar to the small bowel epithelium. Gastric mucosa lined by foveolar cells at the right upper portion. (Hematoxylin and eosin stain; 100×). Right
side: ImmunoRatio was applied to calculate the percentage of positively stained nuclear area (labeling index, DAB: diaminobenzidine area) among
the background hematoxylin stain area (Ki-67 index: DAB/nuclear area = 26.6% in this slide)
Fig. 2 Case selection flow chart. GU: gastric ulcer; EGD: esophagogastroduodenoscopy; IM: intestinal metaplasia
Chen et al. BMC Gastroenterology  (2017) 17:1 Page 3 of 7
components and an adaptive threshold for nuclear area
segmentation (Fig. 1, right side) [21]. Five pictures from
the targeted gastric epithelium adjacent to GU were ap-
plied for digital data analysis. The result was recorded as
a mean Ki-67 labeling index (%).
Statistical methods
To the best of our knowledge, there are no previous re-
ports on peptic ulcer-healing rate or H. pylori eradica-
tion rate following PPI administration in patients with
GU and IM. Because GU patients with H. pylori infec-
tion and IM exhibit gastric epithelial hyperproliferation,
the null hypothesis was that patients with IM had a
higher rate of GU scarring (prediction: 95%) than pa-
tients without IM (80% in our previous study) following
standard triple eradication and PPI therapy [18]. To ob-
tain a power of 0.8 at the significant level of 0.05, the
minimal required number of patients was 70 for each
group. Hence, it was reasonable to enroll at least 140 pa-
tients in this study.
Continuous data were expressed as the mean ± stand-
ard deviation (SD). Continuous data were evaluated
using the paired-t test if the sample size was more than
30 in each group and the Mann–Whitney test was ap-
plied if the sample size was less than 30. The chi-square
test was used for nominal data. Categorical data were
analyzed with the chi-square test or Fisher’s exact test,
where appropriate. All statistical tests were 2-tailed. A
P-value of <0.05 was considered statistically significant.
The correlation coefficients such as Pearson’s correlation
coefficient, Point bi-serial correlation coefficient and
Spearman’s co-efficiency rho were appropriately chosen
based on the data types including numerical, nominal or
ordinal data. A multivariate logistic regression analysis
was applied for the predictors’ evaluation for non-
healing GU and persistent H. pylori infection after
treatment.
Statistical analyses were performed using the Statistical
Package for the Social Science software version 16.0 for
Windows (SPSS, Chicago, IL, USA).
Table 1 Demographics and other characteristics of patients
with gastric ulcer and H. pylori infections
Characteristic IM No IM P value
Number 136 191
Age (years)* 63.3 ± 12.1 59. 3 ± 13.4 0.006
Gender (F/M) 58/78 74/117 0.478
Symptoms
Abdominal pain 100 (73.5%) 149 (78.0%) 0.349
Abdominal fullness 54 (39.7%) 82 (42.9%) 0.560
GERD 14 (10.3%) 17 (8.9%) 0.672
Personal history
Smoking 32 (23.5%) 49 (25.7%) 0.661
Alcohol 24 (17.6%) 32 (16.8%) 0.833
Co morbidity
Cirrhosis 6 (4.4%) 11 (5.8%) 0.589
Uremia 5 (3.7%) 7 (3.7%) 0.996
Diabetic mellitus 28 (20.6%) 34 (17.8%) 0.526
IM type
Complete type 14 (10.3%)
Incomplete type 122 (89.7%)
Gastric ulcer
Wide base (>1.5 cm) 23 (16.9%) 21 (11.0%) 0.122
Location
antrum 62 (45.6%) 101 (52.9%) 0.194
body 74 (54.4%) 90 (47.1%) 0.194
GU-scarring rate 125 (91.9%) 161 (84.3%) 0.040
H. pylori eradication rate 111 (81.6%) 163 (85.3%) 0.368
*Data presented as the mean ± standard deviation; number (%)
IM Intestinal metaplasia, GERD Gastro-esophageal reflux disease, GU-scaring
rate Healed (scarred) gastric ulcer rate (%) following treatment, H. pylori
eradication rate H. pylori eradication success rate following treatment
Table 2 A correlation analysis among factors of non-healing
gastric ulcer, persistent H. pylori infection and other factors, data
are presented as correlation coefficients (Spearmen’s rho)








Wide base ulcer 0.013 0.118*
Persistent Hp 0.209* 1.000
IM −0.113* 0.050
NHGU 1.000 0.209*
DM diabetic mellitus, Wide base ulcer gastric ulcer base more than 1.5 cm, IM
intestinal metaplasia besides the gastric ulcer, Persistent Hp persistent H. pylori
infection after treatment (eradication failure), NHGU non-healing gastric ulcer
after treatment
*P-value < 0.05
Table 3 Predictors for non-healing gastric ulcer after treatment
according to logistic regression analysis
Variables Odds ratio (95% CI) P-value
Age 1.035 (1.007–1.064) 0.015
Persistent Hp 3.924 (1.857–8.294) <0.001
IM 0.366 (0.170–0.792) 0.011
CI confidence interval
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This research was approved by the Institutional Re-
view Board of the Chang-Gung Memorial Hospital (IRB
No: 99-2661B). Written informed consent was obtained
from all enrolled subjects in this study.
Results
We initially included 3412 cases of GU, which were di-
agnosed by EGD and pathologic studies. In total, 136
cases of GU with IM (IM group), and 191 cases of GU
without IM (no IM group) were enrolled in the final
analysis (Fig. 2). Most patients with gastric IM were of
the incomplete type (122/136, 89.7%). Because patients
with atrophic mucosa in histological findings were ex-
cluded in this study, the majority of patients had min-
imal foci of IM and were scored as 0 (absent) or 1 (mild)
(107/136, 78.7%) by using the Sydney system visual ana-
log scale. Only 29 patients with incomplete IM were
scored as 2 (moderate). No patient was scored as 3
(marked).
Demographic and other characteristics of the patients
are listed in Table 1. No significant inter-group differ-
ences were observed in the distribution of gender, symp-
toms, personal history, co-morbidities, GU size and
location. Patients in the IM group were older than those
in the no IM group (mean age, 63.5 ± 12.3 years vs. 59.4
± 13.4 years, P = 0.004). Patients with IM had higher
GU-healing rate than those without IM (92.1% vs. 84.3%,
P = 0.036). However, there were no significant differ-
ences in the H. pylori eradication rates between the two
groups [81.6% (IM group) vs. 85.3% (no IM group), P =
0.405]. A subgroup analysis from 274 patients with suc-
cessful H. pylori eradication was performed and the
result revealed no significant difference in GU healing
rate between patients with IM (104/111, 93.7%) and
those without IM (144/163, 88.3%) (P = 0.125).
The bivariate correlation test revealed that non-
healing GU (NHGU) was positively correlated with age
and persistent H. pylori infection (failure of H. pylori
eradication), but negatively correlated with IM (Table 2).
Because patients with IM were older than those without
IM in this study, multivariate logistical regression
analysis was performed to determine the predictor of
GU healing by adjusting the factor of age (Table 3). As
positive predictors for NHGU, the analysis revealed age
[odds ratio (OR) =1.035, 95% confidence interval (CI) =
1.007–1.064; P = 0.015] and persistent H. pylori infection
[OR = 3.924, 95% CI = 1.857–8.294, P < 0.001]. A nega-
tive predictor was IM [OR = 0.366, 95% CI = 0.170–
0.792, P = 0.011].
For failure of H. pylori eradication, only the factor of
NHGU was a predictor. IM was not a predictor and was
not correlated with failure of H. pylori eradication
(Table 4).
Because this was a retrospective analysis, only
adequate GU biopsy specimens from patients before and
after H. pylori eradication therapy were used for the IHC
stain study. A total of 64 GU biopsy specimens (30 from
patients with non-IM, 34 patients with IM) underwent
Ki-67 staining (Table 5). There was no significant differ-
ence in Ki-67 index between patients with IM and those
without IM. The mean Ki-67 index change before or
after treatment was only marginally different between
patients with IM and those without IM (0.5 ± 1.7 vs. 0.6
± 1.9, P = 0.06).
Discussion
IM is a common pathologic finding in patients with
endoscopy-proven GU [22–24]. Previous studies focused
on the precancerous condition of IM; however, few studies
have investigated the influence of IM on gastric ulcer heal-
ing and H. pylori eradication. Factors such as age, smoking
and H. pylori eradication were reported as important fac-
tors for GU healing [25–27]. In our study, although pa-
tients with gastric mucosal IM had a higher GU healing
rate than those without IM, the GU healing rates were not
significantly different when the focus was on the patients
with successful H. pylori eradication. Multivariate logistic
regression analyses revealed that failure of H. pylori eradi-
cation was a positive predictor (OR = 4.013) and IM was a
negative predictor (OR = 0.369) for non-healing GU.
Hence, successful H. pylori eradication is a more import-
ant predictor than IM for GU healing in this study.
Table 4 Predictors for persistent H. pylori infection after
treatment according to logistic regression analysis
Variables Odds ratio (95% CI) P-value
Wide base ulcer 2.256 (1.053–4.836) 0.036
NHGU 3.808 (1.836–7.896) <0.001
Table 5 Mean Ki-67 stain index in patients before and after H. pylori eradication and maintenance of proton pump inhibitor therapy
for 8 weeks
Ki-67 index No Intestinal metaplasia (n = 30) Intestinal metaplasia (n = 34)
Before After P value Before After P value
Mean index (%) 19.1 ± 15.0 17.3 ± 15.6 0.20 19.8 ± 13.4 17.8 ± 12.2 0.34
Change (%)* 0.6 ± 1.9 0.5 ± 1.7 0.06
*Index change (%) calculated as the mean Ki-67 index (before-after)/before × 100%
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The mechanisms associated with GU healing and repair
include epithelial cell proliferation, growth control, epider-
mal growth factors, angiogenesis and inhibition of acid se-
cretion [12, 13, 28, 29]. Although our original hypothesis
was that cell hyperproliferation in IM might influence GU
healing, we found that there was no significant difference in
cell proliferation Ki-67 stain index between the IM group
and the no IM group. Antigen Ki-67 is a nuclear protein
that is associated with cellular proliferation and ribosomal
RNA transcription. The Ki-67 protein is present during all
active phases of the cell cycle (G1, S, G2 and mitosis), but
is absent from resting cells (G0). In previous studies, pa-
tients with H. pylori infection and chronic gastritis exhib-
ited significantly increased rates of epithelial cell
proliferation. Cell proliferation decreases after successful H.
pylori eradication [30, 31]. Although the mean Ki-67 index
was decreased (decreased cell proliferation) following H.
pylori eradication in our study, there was no significant dif-
ference in mean Ki-67 index between patients with IM and
those without IM. The condition of gastric mucosal cell
proliferation might be due to the status of H. pylori infec-
tion and chronic gastritis, but not the status of IM [30, 31].
There were two limitations in the present study. First,
this study only included patients with GU and IM adja-
cent to GU, but patients with atrophic gastritis were ex-
cluded. It is common to detect atrophic gastritis and IM
coexistence in patients with an H. pylori infection [16–
18]. Although the intra-gastric juice pH value and serum
pepsinogen value are important for the evaluation of
atrophic gastritis and GU healing, these data were not
available in this retrospective study. It would be difficult
to elucidate whether atrophic gastritis or IM has an in-
fluence on GU healing when a patient has both patho-
logic findings of atrophic gastritis and IM in the
stomach. Hence, we excluded the patients with atrophic
gastritis detected via histological examination in this
study. Second, most of the IM types in this study were
mild according to the Sydney system. We could not
compare differences in GU healing between patients
with mild forms of IM and those with marked forms of
IM.
Conclusions
Patients with gastric IM may have a higher GU healing
rate than those without gastric IM. Age, successful H.
pylori eradication and gastric IM were the predictors for
GU healing. However, successful H. pylori eradication
was a more important factor for GU healing than gastric
IM.
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